Teva-Tobramycin · DIN 02389622 · 300 mg/5 mL · Inh Sol-5mL Pk
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Teva-Tobramycin · DIN 02389622
Manufacturer: Teva Canada Limited; listing date 2016-03-30
Health Canada: Marketed since 2016-02-03 · brand TEVA-TOBRAMYCIN · ATC J01GB01 TOBRAMYCIN · form Solution · route Inhalation · ingredients TOBRAMYCIN (TOBRAMYCIN SULFATE) 60 MG/ML · company Teva canada limited · schedule Prescription
Teva-Tobramycin: Formulary list price $41.10 per unit (the source does not state the unit; exact figure $41.0985). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02389622)
Source record
DIN 02389622: Teva-Tobramycin
Raw flags: sec3=Y
Item: 081228094; group id 51; item number 0108; lccId None; manufacturer id TEV
Source form: Inh Sol-5mL Pk; strength: 300mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $41.0985; ministry $41.0985
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02389622
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87512
Therapeutic Notes (formulary)
For the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections.
Tobramycin is administered in alternating periods of 28 days. After 28 days of therapy, patients should stop therapy for the next 28 days, and then resume therapy for the next 28 day on / 28 day off cycle.
Interchangeable products
TOBI · DIN 02239630 · $41.0985
Shortage status: not checked (no credentials)